India's Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) met on Wednesday to consider coronavirus vaccines for emergency use authorisation (EUA) requested by Pfizer-BioNTech, Bharat Biotech and Serum Institute of India(SII).

Pfizer-BioNTech requests more time, India's SEC to meet on January 1 to authorise SII, Bharat Biotech vaccines

Bharat Biotech, the maker of one of India's leading COVID-19 vaccine candidates said on Tuesday its recruitment of volunteers for a late-stage trial of the shot is half done.

Bharat Biotech recruits 13,000 volunteers for Phase III trials of Covaxin

The interim findings of phase 1 clinical trial of COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events.

Bharat Biotech's phase 1 trial findings show COVID-19 vaccine well tolerated; no serious adverse events

In India, the head of the Serum Institute which has tasked to develop the AstraZeneca based Covishield vaccine in the country now says, that the positive late state trial results of the candidates will allow it to seek emergency use approval by the year end.

Serum Institute, Bharat Biotech vaccines applied for emergency use in India

In a major development related to COVID-19 vaccine, Subject Expert Committee (SEC) of Drugs Controller General of India (DCGI) has asked for more safety and efficacy data from Serum Institute of India (SII) and Bharat Biotech for their COVID-19 vaccines.

DCGI expert panel asks SII, BHARAT Biotech to provide more safety, efficacy data for Covid-19 vaccines

India's ministry of health and family welfare dismissed a media report about the rejection of vaccines developed by Serum Institute of India(SII) and Bharat Biotech as "fake".

Fake report on rejection of vaccines by Serum Institute, Bharat Biotech: Government

Ambassadors and High Commissioners of around 60 countries have landed in Hyderabad, India to visit Bharat Biotech headquarter and Biological E limited which are working on the COVID-19 vaccine.

India: Envoys from 60 nations arrived in Hyderabad to visit Bharat-Biotech HQ

Ambassadors and High Commissioners of around 80 countries will be landing in Hyderabad, India on December 9 to visit Bharat Biotech and BE limited which are working on the COVID-19 vaccine.

India: Envoys from 80 nations to visit Bharat-Biotech HQ

Indian Pharmaceuticals firm Bharat Biotech is seeking emergency authorisation of its Coronavirus vaccine 'Covaxin'. This comes after Pfizer & Serum institute producing AstraZeneca vaccine have applied for the emergency use authorisation from DGCI.

India: Bharat Biotech latest to seek emergency use authorisation

The Hyderabad-based pharmaceutical firm Bharat Biotech applied to the Drugs Controller General of India (DCGI) on Monday for granting emergency use authorisation for its COVID-19 vaccine Covaxin, becoming the third company after American pharma giant Pfizer and Pune-based Serum Institute of India (SII) to seek emergency use authorisation for its Covid-19 vaccine candidate.

Bharat Biotech seeks emergency use authorisation for Indian Covid-19 vaccine; expert panel to review

Prime Minister Narendra Modi on Saturday, visited Bharat Biotech, a Hyderabad-based Pharmaceutical company to know about the progress made in the development of indigenous coronavirus vaccine.

Bharat Biotech working with ICMR for speedy progress on vaccine: PM Modi

Prime Minister Narendra Modi on Saturday concluded his visit to Zydus Biotech Park in Ahmedabad after reviewing the development of COVID-19 vaccine candidate ZyCOV-D.

PM Modi concludes Zydus Biotech Park visit, next stop Bharat Biotech facility in Hyderabad

As countries compete to grab doses of the vaccines, the world is turning to India for vaccine supplies. India's plays a vital role in the vaccine chain. India is the world's vaccine manufacturing hub and is known for its pharmacy in vaccine production.

Amid race for vaccine, world turns to India for vaccine supply

India's pharmaceutical company Bharat Biotech International Ltd has now, months later, revealed that during Phase 1 of the human trial of COVID-19 vaccine, the company had an adverse event.

Bharat Biotech reveals adverse event during Phase 1 trial of COVID-19 vaccine

India's Bharat Biotech this week offered Brazil a COVID-19 vaccine that is in late-stage clinical trials and a possible technology transfer partnership, a company executive said on Friday.

Bharat Biotech offers Brazil potential coronavirus vaccine

India is racing ahead with work on its coronavirus vaccine as countries around the world sought to conquer the pandemic and rescue their economies. Also read: These three Indian companies are ready to produce Covid-19 vaccine Companies like Zydus Cadila, Serum Institute and Bharat Biotech are at the forefront of research on covid vaccines and are likely to be among the leading manufacturers as and when their commercial application is permitted.

Oxford COVID-19 vaccine to be available for Indians by April 2021: Serum Institute Chief 

India is racing ahead with work on its coronavirus vaccine as countries around the world sought to conquer the pandemic and rescue their economies. Also read | Volunteers face 'severe hangover', headache and pain after getting Pfizer vaccine shot Companies like Zydus Cadila, Serum Institute and Bharat Biotech are at the forefront of research on covid vaccines and are likely to be among the leading manufacturers as and when their commercial application is permitted.

These three Indian companies are ready to produce Covid-19 vaccine

India's Bharat Biotech, which is developing a coronavirus vaccine has said that the indigenous candidate to counter the coronavirus pandemic may be ready by June 2021.

Coronavirus vaccine may be ready by June 2021: Bharat Biotech

Serum Institute of India and Bharat Biotech are expected to pursue late stage clinical trials of intranasal COVID-19 vaccines in the coming months once they receive regulatory approval, India`s health minister said on Sunday.

Serum Institute, Bharat Biotech to begin trial of intranasal COVID-19 vaccine soon

Pharma major Bharat Biotech has announced the development of India’s 1st vaccine candidate for COVID-19, named COVAXIN

Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval

An intranasal vacccine for COVID-19 is under development by Indian pharma company Bharat Biotech. It announced yesterday that a unique intranasal vacccine named 'CoroFlu' is under development.

Indian pharma begins development and testing of COVID-19 vaccine

bharat-biotech

Bharat Biotech, News on Bharat Biotech, stories on Bharat Biotech, articles on Bharat Biotech, Bharat Biotech stories at Wion, Bharat Biotech news, Bharat Biotech latest news

bharat biotech